RMP
GSK icon

Richards, Merrill & Peterson’s GSK GSK Stock Holding History

Richards, Merrill & Peterson’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,024
Closed -$39.7K – 319
2025
Q1 		$39.7K Hold
1,024
– – 0.02% 275
2024
Q4 		$34.6K Buy
+1,024
New +$36.9K 0.02% 276

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Richards, Merrill & Peterson's GSK Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of GSK (GSK) in Q2 2025, closing a stake of 1,024 shares — an estimated $39.7K sold.

Richards, Merrill & Peterson first reported a position in GSK in Q4 2024 and held it in 2 quarters. The position peaked at $39.7K in Q1 2025. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 1,024 GSK shares in Q2 2025, an estimated $39.7K.
  • Richards, Merrill & Peterson first reported a position in GSK in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's GSK position peaked at $39.7K in Q1 2025.
  • 890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.